From data to desire: How Pharma learned to win the Super Bowl Pharma marketing exec on how health brands are trading clinical claims for cultural currency—and what the FDA's latest warning means for the future.

Pharma traded clinical claims for cultural currency at this year’s Super Bowl—but the FDA’s warning to Novo Nordisk shows emotional resonance has limits. Behavioral science is the new frontier in health marketing. #PharmaMarketing #SuperBowl #HealthTech #BehavioralScience #FDA

How LSD and classic psychedelics are re-entering modern psychiatry Definium's CMO talks about evaluating psychedelic medicine(s) in the modern era and developing novel treatments for mental health disorders.

The psychedelic renaissance is here. 🧠 Our latest feature explores how LSD is being rigorously researched for anxiety & depression. We spoke with Definium's Dr. Dan Karlin about the science, the stigma, and the future of mental health care. #MentalHealth #LSD #PsychedelicScience #DrugDevelopment

How digital twins are pioneering a new era of personalized, longitudinal healthcare Dr. Amanda Randles explains how they are developing digital twins to move medicine beyond static snapshots to dynamic, personalized care.

Duke's Dr. Amanda Randles explains how #DigitalTwins move medicine beyond static snapshots to dynamic, personalized care. Combining #AI, wearables & supercomputing to predict disease before symptoms appear.

#HealthTech #AI #FutureOfMedicine #DigitalHealth

Scaling impact without leaving medicine  Dr Bryony Henderson, a former frontline GP, on reframing your career, overcoming guilt, and finding purpose at scale.

"I didn't leave medicine—I'm just practicing it differently." 🩺

Former GP Dr Bryony Henderson on evolving from frontline care to system-wide impact as Head Medical Director at HeliosX.

#HealthcareCareers #ClinicalLeadership #PhysicianBurnout #HealthTech #CareerPivot #MedicalDirector #HeliosX

ECCO26 data reinforce long-term durability and real-world impact of AbbVie’s IBD portfolio Real-world data and three-year trial results show sustained remission and symptom control with Skyrizi and Rinvoq.

New data at ECCO 2026: Risankizumab & upadacitinib show sustained remission & real-world impact in UC & Crohn’s. Experts discuss 3-year durability, rapid symptom control & what it means for patients.
#News #ECCO26 #IBD #SKYRIZI #RINVOQ #RealWorldEvidence #AbbVie

Why Pharma can’t ignore friendshoring in supply chain Bora Pharma exec, J.D. Mowery, discusses how geopolitical shifts are reshaping pharmaceutical manufacturing and supply chain strategy.

J.D. Mowery of Bora Pharmaceuticals explains why "friendshoring" is more than a buzzword—it's about patient-centric supply chains, geopolitical resilience, and rethinking manufacturing strategy for 2026 and beyond.
#News #Pharma #SupplyChain #Friendshoring #CDMO #Manufacturing #BoraPharmaceuticals

Sensei Bio stock skyrockets on acquisition and $200m financing Sensei stock surges after acquiring Faeth Therapeutics and securing $200 million private placement to advance cancer pipeline.

Sensei Biotherapeutics stock skyrockets 206% after acquiring Faeth Therapeutics and securing $200M private placement. The deal advances PIKTOR, a promising PI3K/mTOR inhibitor for endometrial and breast cancer.
#News #SenseiBio #Biotech #CancerResearch #StockNews #PIKTOR

Evogene and Australian Uni partner to tackle chemotherapy resistance in lung cancer AI-driven collaboration between the Israeli company and Queensland University of Technology targets cellular pathways to overcome treatment hurdles in non-small cell lung cancer.

Evogene and QUT team up to fight chemotherapy resistance in lung cancer using AI. The collaboration targets cellular pathways to develop new therapies for patients with limited options.
#News #Evogene #QUT #AI #CancerResearch #LungCancer #Biotech #DrugDiscovery

Seamflow secures $4.5m to deploy AI for testing and certification bottlenecks London-based AI startup raises seed funding to tackle certification delays in medical devices and industrial sectors.

Seamflow raises $4.5M to bring AI to the Testing, Inspection and Certification industry. Its platform tackles certification backlogs—cutting medical device approval times from 20+ months.

#News #MedTech #AI #HealthTech #VentureCapital #TIC

RevealDx wins FDA clearance for lung nodule assessment software New AI software aims to help radiologists assess lung nodule cancer risk and improve early detection.

FDA clears RevealDx's AI-powered lung nodule software to help radiologists assess cancer risk. The tool integrates directly into PACS and is now Medicare reimbursable.

#News #HealthTech #AI #FDA #LungCancer #MedicalImaging #Radiology

Inside Immunai’s plan to map the entire immune system Immunai CEO Noam Solomon details four pivotal studies shaping the future of immunology and oncology research, as part of the ‘Grand Collaboration’.

Immunai CEO Noam Solomon reveals how four new studies—spanning autoimmune disease, cell therapy toxicity, and cancer—are mapping the immune system to unlock safer, personalized treatments. 🧬🔬
#Immunology #AI #Biotech #PrecisionMedicine #CellTherapy #DrugDevelopment

2025 in Review: Global biotech and funding trends Deepali Suri, President of ICON Biotech, discusses Asia’s clinical trial boom, funding shifts, and why neurology and cardiology are surpassing oncology.

New ICON Biotech survey reveals: China now conducts 25% of global clinical trials. Neurology & cardiology overtaking oncology in R&D focus. Plus insights on funding, AI, and talent. Read the full Q&A.
#Biotech #ClinicalTrials #PharmaInnovation #AI

How ambient AI is capturing healthcare’s unheard data The Sciensus team discusses how ambient AI captures patient sentiment to augment nurses, personalise care, and help keep patients healthier at home.

How can AI improve healthcare? By listening. Sciensus uses ambient AI to capture patient insights & give nurses more time for human care. Transforming the patient experience. #FutureOfHealthcare #AIforGood #NurseTech #Microsoft #PatientCentric

CAR T enters a new era of in vivo reprogramming of T cells Vyriad's Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.

The CAR T field is shifting to in vivo platforms that aim to make powerful cell therapies simpler, cheaper, and more accessible. Insights from Vyriad's Luke Russell. #CARTcell #immunotherapy #invivo #biotech #Vyriad #oncology #celltherpay

Building resilient pharmaceutical supply chains in an era of disruption Kum Ming Woo advises prioritizing supplier quality & availability over cost, emphasizing geographic diversification and stage-appropriate strategies.

Cost shouldn’t be your first question in pharma supply chains, says Vector Labs’ Kum Ming Woo. Prioritize quality & availability, diversify geographically, and adopt stage-appropriate strategies.

#Interview #Expert #Pharma #SupplyChain #Biotech #Resilience #DrugDevelopment

Rapid Nexus study challenges neuropathy as the point of no return New peer-reviewed research indicates nerve function is key to healing tissue once considered unsalvageable.

New study from Rapid Nexus challenges old view of nerve damage. Research shows targeting neuropathy can heal tissue once considered unsalvageable, helping patients avoid amputation.
#News #Diabetes #WoundCare #Neuropathy #MedicalInnovation #Research

Hospital of 2026: Local LLMs and AI Are Redefining Healthcare myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.

In 2026, hospitals will split between running their own local AI and forming trusted partnerships, while certified AI medical devices gain major trust, says myTomorrow's Danny den Hamer.
#AIinHealthcare #HealthTech2026 #SaMD #LLM #DigitalHealth #Tends

Arkin Bio Ventures III: $100 million fund for transformative therapies Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.

Arkin Capital launches $100M Arkin Bio Ventures III to back transformative biotech companies. The fund takes a hands-on, science-driven approach as an active partner from day one.
#News #Interview #Biotech #VentureCapital #Therapeutics #DrugDiscovery

Becton Dickinson and ten23 partner on wearable injector supply Partnership will support the supply for Becton, Dickinson and Company's self-administered therapies with a ready-to-use, scalable platform.

ten23 health & BD partner to enable supply chain readiness for the BD Libertas wearable injector. The full-service solution aims to speed development of large-volume, self-administered therapies.

#News #SupplyChain #WearableInjector #Biotech #Pharma #DrugDelivery #Partnership

Genesipre’s rare disease therapy gets orphan drug status in the US and Europe The gene therapy is being developed to treat a rare pediatric metabolic disease, methylmalonic acidemia (MMA).

Genesipre’s gene therapy GENE202 has received Orphan Drug Designation for methylmalonic acidemia (MMA), a rare pediatric disease.
#News #GeneTherapy #RareDisease #OrphanDrug #MMA #Biotech

Boehringer picks AI imaging tech as co-primary endpoint for IPF trial Brainomix's e-Lung AI will provide quantitative imaging biomarkers as a co-primary endpoint in Boehringer Ingelheim's Phase III DROP-FPF study.

Brainomix's AI imaging tech will serve as a co-primary endpoint in Boehringer Ingelheim's Phase 3 DROP-FPF trial for pulmonary fibrosis—a first for ILD studies. #AI #News #ClinicalTrials #PulmonaryFibrosis #MedicalImaging #Brainomix

VCU researchers win $1.8 million US DoD grant for cancer therapy The US Department of Defense (DoD) grant funds engineered NK cell therapy for resistant prostate cancer.

VCU researchers awarded $1.8M DoD grant to develop a novel engineered NK cell therapy targeting incurable, advanced prostate cancer (CRPC).
#News #ProstateCancer #Immunotherapy #CRPC #CellTherapy #NKcells #IL24 #DoDgrant

The New Gold Rush: High-stakes race for multi-cancer blood tests Abbott's $21 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Ming talks about the major players in the sector and hurdles.

Abbott’s $21B acquisition of Exact Sciences signals a new era in cancer detection. We analyze the high-stakes MCED market, pivotal FDA decisions, and the reimbursement battle ahead with Gabelli Funds’ Elena Meng.

#MCED #cancerscreening #Abbott #ExactSciences #healthcareinvesting #biotech

Stereotaxis MAGiC catheter cleared by FDA for robotic heart ablation The US FDA approves Stereotaxis' robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.

FDA approves Stereotaxis MAGiC robotic ablation catheter. A breakthrough for treating complex heart arrhythmias with precise magnetic navigation.
#News #Stereotaxis #FDAapproval #cardiology #robotics #arrhythmia #healthtech

Examining the growing delays in clinical trial start-up ICON exec discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.

Clinical trial start-up delays are rising due to complex protocols & contract bottlenecks. ICON survey data reveals 55% of sites take 5+ months to activate. Solutions require site-centricity & smarter tech.
#Interview #ClinicalTrials #StudyStartup #SiteCentricity #ICON #DrugDevelopment

Eisai subsidiary starts Phase III trial for Schizophrenia drug in Japan EA Pharma initiates a pivotal study of the novel glutamate modulator, evenamide, for treatment-resistant schizophrenia in Japan.

EA Pharma (Eisai) starts Phase III trial in Japan for evenamide, a novel glutamate modulator for schizophrenia.
The drug was licensed as part of a €117M deal with Newron Pharmaceuticals.

#News #Schizophrenia #ClinicalTrial #MentalHealth #Biotech #Eisai #Evenamide

Canopy raises $22 million for healthcare safety platform The Series B funding is expected to finance the expansion of Canopy’s connected safety platform across US health systems.

Canopy secures $22M Series B to expand its connected safety platform for combating workplace violence and modernize hospital operations with location intelligence.
#News #HealthTech #SeriesB #WorkplaceSafety #Innovation #LocationIntelligence

Endometriosis study uncovers molecular subgroups to guide trials Endogene.bio’s research reveals how single-cell analysis predicts drug efficacy, enabling targeted treatments for endometriosis subgroups.

New #research by endogene.bio reveals why #endometriosis treatments often fail. The study identifies molecular subgroups & predicts drug response, suggesting non-invasive monitoring via menstrual blood could guide precision therapy.
#News #WomensHealth #PrecisionMedicine #ClinicalTrials

ASH25: Gallop’s LYT-200 shows unprecedented survival in AML The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.

Gallop’s LYT-200 shows 13.2-month median survival in late-line AML at #ASH2025—far exceeding historic benchmarks. The anti-galectin-9 antibody combines strong efficacy with a clean safety profile.

#News #Leukemia #Oncology #Biotech #ClinicalTrials #AML

SweetBio’s honey-based bandage saving limbs and closing wounds The US-based company’s CEO talks about how novel biomaterial tackles the hidden crisis of chronic wounds, blending ancient remedies with modern science to prevent amputations.

Healing chronic wounds twice as fast? SweetBio’s honey-based biomaterial is tackling the hidden amputation crisis, blending ancient remedies with cutting-edge science. #News #WoundCare #Diabetes #MedTech #Innovation #Biomaterials #DiabeticFootUlcer